These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21317599)

  • 21. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
    Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
    Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.
    Clay E; Khemiri A; Zah V; Aballéa S; Ruby J; Asche CV
    J Med Econ; 2014 Sep; 17(9):626-36. PubMed ID: 24841329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigation of Simulated Adherence in Long-Term Buprenorphine/Naloxone Treatment Patients.
    Rahman N; Janardhanan A; Shikalgar S; Pirkhan MA; Canner J; Skipwith C; Noor-E-Alam M
    Subst Use Misuse; 2024; 59(9):1275-1279. PubMed ID: 37950394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A trial of integrated buprenorphine/naloxone and HIV clinical care.
    Sullivan LE; Barry D; Moore BA; Chawarski MC; Tetrault JM; Pantalon MV; O'Connor PG; Schottenfeld RS; Fiellin DA
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S184-90. PubMed ID: 17109305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk reduction with buprenorphine-naloxone and methadone: patient's choice.
    Newman RG
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):e142. PubMed ID: 25197828
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of adolescent opioid dependence: no quick fix.
    Fiellin DA
    JAMA; 2008 Nov; 300(17):2057-9. PubMed ID: 18984896
    [No Abstract]   [Full Text] [Related]  

  • 27. Authors' reply: "Risk reduction with buprenorphine-naloxone and methadone: patient's choice".
    Woody G; Bruce D; Korthuis PT; Chhatre S; Hillhouse M; Jacobs P; Sorensen J; Saxon AJ; Poole S; Metzger D; Ling W
    J Acquir Immune Defic Syndr; 2014 Dec; 67(5):e142-3. PubMed ID: 25243431
    [No Abstract]   [Full Text] [Related]  

  • 28. The Need to Rule Out Intranasal Self-administration of Buprenorphine-Naloxone Combinations Before Prescribing Buprenorphine Without Naloxone.
    Mendelson J
    J Addict Med; 2023 Jan-Feb 01; 17(1):119. PubMed ID: 35914117
    [No Abstract]   [Full Text] [Related]  

  • 29. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.
    Gunderson EW; Wang XQ; Fiellin DA; Bryan B; Levin FR
    Addict Behav; 2010 May; 35(5):537-40. PubMed ID: 20106601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting.
    Leshner AI
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S103-4. PubMed ID: 12738354
    [No Abstract]   [Full Text] [Related]  

  • 32. Opioid dependence treatment, including buprenorphine/naloxone.
    Raisch DW; Fye CL; Boardman KD; Sather MR
    Ann Pharmacother; 2002 Feb; 36(2):312-21. PubMed ID: 11847954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients.
    Vergara-Rodriguez P; Tozzi MJ; Botsko M; Nandi V; Altice F; Egan JE; O'Connor PG; Sullivan LE; Fiellin DA;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S62-7. PubMed ID: 21317596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescription drug monitoring programs and buprenorphine maintenance: clinical considerations.
    Hoefer M; Petrakis I
    Am J Addict; 2014; 23(6):616-7. PubMed ID: 25251308
    [No Abstract]   [Full Text] [Related]  

  • 35. Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims.
    Khemiri A; Kharitonova E; Zah V; Ruby J; Toumi M
    Postgrad Med; 2014 Sep; 126(5):113-20. PubMed ID: 25295655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States.
    Asche CV; Clay E; Kharitonova E; Zah V; Ruby J; Aballéa S
    J Med Econ; 2015; 18(8):600-11. PubMed ID: 25851505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is daily supervised buprenorphine-naloxone dosing necessary?
    Kleinman RA; Nielsen S; Weiss RD
    BMJ; 2022 Aug; 378():e071467. PubMed ID: 35973725
    [No Abstract]   [Full Text] [Related]  

  • 38. Buprenorphine and HIV primary care: report of a forum for collaborative HIV research workshop.
    Miller V;
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S254-7. PubMed ID: 17109312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Models for integrating buprenorphine therapy into the primary HIV care setting.
    Basu S; Smith-Rohrberg D; Bruce RD; Altice FL
    Clin Infect Dis; 2006 Mar; 42(5):716-21. PubMed ID: 16447120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
    Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.